肿瘤防治研究2011，Vol.38Issue(11)：1268-1271,4.DOI:10.3971/j.issn.1000-8578.2011.11.013
非小细胞肺癌中CAR和CD46的表达及临床意义
Expressions and Clinical Signficances of CAR and CD46 in Non-small Cell Lung Cancer
摘要
Abstract
Objective To investigate the expressions of coxsackie and adenovirus receptor (CAR) and group B adenovirus receptor (CD46) in human non-small cell lung cancer (NSCLC) and its clinical significance. Methods The expressions of CAR and CD46 were detected by immunohistochemical technique in 144 cases of NSCLC and the relationships were analyzed between the expressions of CAR or CD46 and the transfection efficiency of adenovirus or development of NSCLC. Results In 144 samples from NSCLC patients, the expression rates of CAR in squmaous cell carcinoma and adenocarcinoma were 77. 5% (31/40) and 36. 8%(14/38) and CD46 were 58. 3%(14/24) and 88. 1K(37/42). There were significant differences between CAR and CD46 expression in the squmaous cell carcinoma and adenocarcinoma (P<0. 05). Meanwhile, CAR positive rate was 43. 3%(13/30) in TNM stage I patients and 66. 7% (32/48) in stage Ⅱ～Ⅲ patients, (P<0. 05). The results showed that CAR expression was closely related to the clinical TNM staging in NSCLC. Conclusion The expression levels and pattern of CAR and CD46 were significantly different in various pathological types of NSCLC. Positive expression of CAR u-sually in squamous cell carcinoma, while CD46 is in adenocarcinoma, indicated that different receptor-dependent adenovirus might have transfection efficiency in various pathologic types of NSCLC. Expression of CAR protein is also correlated to the malignant degree of NSCLC. CAR might play an important roles in evalution of prognosis of NSCLC.关键词
非小细胞肺癌/柯萨奇-腺病毒受体/CD46/基因治疗Key words
NSCLC/ Coxsackie and adenovirus receptor/CD46/ Gene therapy分类
医药卫生引用本文复制引用
马玲娣,刘乾,王勇,王仕忠,鲍永仪,关乃富,倪诚,樊小龙..非小细胞肺癌中CAR和CD46的表达及临床意义[J].肿瘤防治研究,2011,38(11):1268-1271,4.基金项目
江苏省社会发展基金资助项目(BS2007025) （BS2007025）
